The cancer and inflammatory drug development company will list its Level II ADRs on the NYSE MKT on Tuesday , November 19, 2013 under the ticker symbol “CANF”.
Israeli Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), Cancer and inflammatory drug development company, announced today that its Level II American Depository Receipts (“ADRs”) have been approved for listing on the NYSE MKT. Trading will begin on Tuesday, November 19, 2013 under the ticker symbol “CANF”. Prior to that date, Can-Fite’s ADRs will continue to trade on the U.S. Over-the-Counter Markets (OTCQB: CANFY).
“We are excited about the NYSE MKT listing, which should enable us to increase the trading liquidity of our ADRs, broaden our shareholder base, raise our profile in the investment community and provide us a platform to share our value proposition and communicate our strategy with a broader group of investors, ” stated Can-Fite’s Chief Executive Officer, Dr. Pnina Fishman. “Our move to the NYSE MKT reflects Can-Fite’s commitment to the U.S. financial markets and our goal to meet the highest standards of disclosure and corporate governance. As our portfolio of indications moves into more advanced stages of clinical development, we believe we will be in a position to pursue additional licensing agreements with some of the world’s leading pharmaceutical companies. To support this business development, we are increasing the global visibility of our Company through this NYSE MKT listing, ” added Dr. Fishman.
“We are excited to welcome Can-Fite to the NYSE community and look forward to a long-term partnership with the company and its U.S. shareholders, ” said Scott Cutler, Executive Vice President, Head of Global Listings, NYSE Euronext. “As a forward-thinking biotech company with a global reach, Can-Fite is a great example of a growth oriented company that can leverage the NYSE’s advanced and innovative market model.”
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the “TASE”) (TASE: CFBI).
The company founded in 2000, by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., on the basis of her scientific findings, and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular, ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and are suggested as a biological predictive marker.